Home » Business News » 2012 » March » March 16, 2012

BB Biotech AG completed its current share buyback program

March 16, 2012 - London

BB BIOTECH AG /BB Biotech AG completed its current share buyback program. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

On March 15, 2012, BB Biotech AG completed its current share buyback program which was initiated on December 2, 2011. During this period a total of 1 024 150 registered shares were bought back through the second trading line.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, Tel. +41 44 267 67 00,

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1 bn in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

BB Biotech Press Release (PDF)

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: BB BIOTECH AG via Thomson Reuters ONE



Comment on this story